Commutability Assessment of Candidate Reference Materials for Lipoprotein(a) by Comparison of a MS-based Candidate Reference Measurement Procedure with Immunoassays.


Journal

Clinical chemistry
ISSN: 1530-8561
Titre abrégé: Clin Chem
Pays: England
ID NLM: 9421549

Informations de publication

Date de publication:
01 03 2023
Historique:
received: 28 03 2022
accepted: 02 11 2022
pubmed: 17 1 2023
medline: 4 3 2023
entrez: 16 1 2023
Statut: ppublish

Résumé

Elevated concentrations of lipoprotein(a) [Lp(a)] are directly related to an increased risk of cardiovascular diseases, making it a relevant biomarker for clinical risk assessment. However, the lack of global standardization of current Lp(a) measurement procedures (MPs) leads to inconsistent patient care. The International Federation for Clinical Chemistry and Laboratory Medicine working group on quantitating apolipoproteins by mass spectrometry (MS) aims to develop a next-generation SI (International system of units)-traceable reference measurement system consisting of a MS-based, peptide-calibrated reference measurement procedure (RMP) and secondary serum-based reference materials (RMs) certified for their apolipoprotein(a) [apo(a)] content. To reach measurement standardization through this new measurement system, 2 essential requirements need to be fulfilled: a sufficient correlation among the MPs and appropriate commutability of future serum-based RMs. The correlation among the candidate RMP (cRMP) and immunoassay-based MPs was assessed by measuring a panel of 39 clinical samples (CS). In addition, the commutability of 14 different candidate RMs was investigated. Results of the immunoassay-based MPs and the cRMPs demonstrated good linear correlations for the CS but some significant sample-specific differences were also observed. The results of the commutability study show that RMs based on unspiked human serum pools can be commutable with CS, whereas human pools spiked with recombinant apo(a) show different behavior compared to CS. The results of this study show that unspiked human serum pools are the preferred candidate secondary RMs in the future SI-traceable Lp(a) Reference Measurement System.

Sections du résumé

BACKGROUND
Elevated concentrations of lipoprotein(a) [Lp(a)] are directly related to an increased risk of cardiovascular diseases, making it a relevant biomarker for clinical risk assessment. However, the lack of global standardization of current Lp(a) measurement procedures (MPs) leads to inconsistent patient care. The International Federation for Clinical Chemistry and Laboratory Medicine working group on quantitating apolipoproteins by mass spectrometry (MS) aims to develop a next-generation SI (International system of units)-traceable reference measurement system consisting of a MS-based, peptide-calibrated reference measurement procedure (RMP) and secondary serum-based reference materials (RMs) certified for their apolipoprotein(a) [apo(a)] content. To reach measurement standardization through this new measurement system, 2 essential requirements need to be fulfilled: a sufficient correlation among the MPs and appropriate commutability of future serum-based RMs.
METHODS
The correlation among the candidate RMP (cRMP) and immunoassay-based MPs was assessed by measuring a panel of 39 clinical samples (CS). In addition, the commutability of 14 different candidate RMs was investigated.
RESULTS
Results of the immunoassay-based MPs and the cRMPs demonstrated good linear correlations for the CS but some significant sample-specific differences were also observed. The results of the commutability study show that RMs based on unspiked human serum pools can be commutable with CS, whereas human pools spiked with recombinant apo(a) show different behavior compared to CS.
CONCLUSIONS
The results of this study show that unspiked human serum pools are the preferred candidate secondary RMs in the future SI-traceable Lp(a) Reference Measurement System.

Identifiants

pubmed: 36644921
pii: 6987870
doi: 10.1093/clinchem/hvac203
doi:

Substances chimiques

Lipoprotein(a) 0
LPA protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

262-272

Informations de copyright

© American Association for Clinical Chemistry 2023.

Auteurs

Ioannis Dikaios (I)

European Commission, Joint Research Centre (JRC), Geel, Belgium.

Harald Althaus (H)

Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany.

Eduardo Angles-Cano (E)

French Institute of Health and Medical Research (INSERM) Université Paris Cité, Paris, France.

Uta Ceglarek (U)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Leipzig, Germany.
LIFE-Leipzig Research Center for Civilization Diseases, University of Leipzig, Leipzig, Germany.
Division Clinical Mass Spectrometry of the German Society of Clinical Chemistry and Laboratory Medicine (DGKL), Berlin, Germany.

Stefan Coassin (S)

Institute of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria.

Christa M Cobbaert (CM)

Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands.

Vincent Delatour (V)

Laboratoire National de Métrologie et d'Essais, Paris, France.

Benjamin Dieplinger (B)

Department of Laboratory Medicine, Konventhospital Barmherzige Brueder Linz and Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria.

Matthias Grimmler (M)

DiaSys Diagnostic Systems GmbH, Holzheim, Germany.

Andrew N Hoofnagle (AN)

Department of Laboratory Medicine and Pathology, University of Washington, Seattle, USA.

Gerhard M Kostner (GM)

Division of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria.

Florian Kronenberg (F)

Institute of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria.

Zsusanna Kuklenyik (Z)

Division of Laboratory Sciences, Centers for Disease Control and Prevention (CDC), Atlanta, USA.

Alicia N Lyle (AN)

Division of Laboratory Sciences, Centers for Disease Control and Prevention (CDC), Atlanta, USA.

Urban Prinzing (U)

Roche Diagnostics GmbH, Penzberg, Germany.

L Renee Ruhaak (LR)

Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands.

Hubert Scharnagl (H)

Division of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria.

Hubert W Vesper (HW)

Division of Laboratory Sciences, Centers for Disease Control and Prevention (CDC), Atlanta, USA.

Liesbet Deprez (L)

European Commission, Joint Research Centre (JRC), Geel, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH